NCT02539719View on ClinicalTrials.gov

Study of SC-003 Alone and in Combination With ABBV-181 in Subjects With Platinum-Resistant/Refractory Ovarian Cancer

PHASE1TerminatedINTERVENTIONAL

Enrollment

74

Participants

Timeline

Start Date

August 31, 2015

Primary Completion Date

January 2, 2019

Study Completion Date

January 2, 2019

Conditions

Ovarian Cancer

Interventions

DRUG

SC-003

DRUG

SC-003 in combination with ABBV-181

Trial Locations (16)

10065

New York

19111

Philadelphia

37203

Nashville

43210

Columbus

48201

Detroit

48202

Detroit

55905

Rochester

60208

Evanston

60637

Chicago

63130

St Louis

72703

Fayetteville

73104

Oklahoma City

75230

Dallas

77030

Houston

91010

Duarte

02114

Boston

Sponsors

Lead Sponsor

All Listed Sponsors

lead

Stemcentrx

INDUSTRY